Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azithromycin ophthalmic - InSite Vision

Drug Profile

Azithromycin ophthalmic - InSite Vision

Alternative Names: AzaSite; Azasite; AzaSite Xtra; azithromycin ophthalmic 1%; azithromycin ophthalmic 2%; ISV-401; ISV-405; SJP-0118

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSite Vision
  • Developer Akorn; InSite Vision; Merck & Co; Senju Pharmaceutical; Tottori University Hospital
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Conjunctivitis

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • No development reported Blepharitis; Chalazion
  • Discontinued Infectious keratitis

Most Recent Events

  • 17 Jul 2019 Registered for Infectious conjunctivitis in Japan before July 2019 (Ophthalmic) (Senju pharmaceutical pipeline July 2019)
  • 13 Jun 2018 No development reported - Phase-III for Blepharitis in Japan (Instillation)
  • 13 Jun 2018 No development reported - Phase-III for Chalazion in Japan (Instillation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top